Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00883116 · ClinicalTrials.gov registry record · Phase 3
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
A Phase 3 study, sponsored by R-Pharm.
- Terminated
- Registry status
- Phase 3
- Development phase
- 551
- Enrollment target
NCT00883116: Clinical Trial Phase 3 study, sponsored by R-Pharm.
NCT00883116 is a Phase 3 study that was terminated before completion, run by R-Pharm. The registered enrollment target is 551 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00883116, a Phase 3 study, was terminated before completion, sponsored by R-Pharm.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 551 participants
- Enrollment target
Study Summary
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.
Primary Outcome
Survival was defined as the time from the date of randomization until the date of death. If the patient did not die, OS was censored on the last date he or she was known to be alive.
Interventions
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2009-08 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Why NCT00883116 stopped before completion
NCT00883116 is an interventional study that assigns participants to a tested intervention. The registered 551 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 3 interventions - of which Doxorubicin is the first listed.
NCT00883116 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00883116 about?
NCT00883116 is a clinical study titled "A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer". The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed follo...
What is the current status of trial NCT00883116?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 551 participants. The study started on 2009-08. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00883116?
The interventions under investigation include: Doxorubicin (DRUG), Paclitaxel (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00883116?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00883116's enrollment target sits among peer trials
551 680th of 2000 higher than 1,321 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia